Assessment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Counts in 2,126 Patients: 20 Years of Experience at The University of Texas M.D. Anderson Cancer Center

作者: Apostolia M. Tsimberidou , Sijin Wen , Susan O'Brien , Peter McLaughlin , William G. Wierda

DOI: 10.1200/JCO.2006.09.4508

关键词: Differential diagnosisProportional hazards modelLeukemiaTreatment outcomeCancerInternal medicineChronic lymphocytic leukemiaOncologyImmunologyLymphocyteLymphocytic lymphomaMedicine

摘要: Purpose Chronic lymphocytic leukemia (CLL) and small lymphoma (SLL) are currently considered the same entity, but controversy remains over whether CLL SLL should be treated similarly. We assessed characteristics of patients with differ in ways other than absolute lymphocyte count (ALC) evaluated treatment outcomes prognostic factors. Methods searched electronic database for or who presented to The University Texas M.D. Anderson Cancer Center (Houston, TX) between 1985 2005. reviewed patient records determine presenting characteristics, treatment, clinical outcomes. Cox models using training validation sets resampling methods were used develop a model predicting survival. Results Among 2,126 consecutive CLL/SLL patients, 312 (15%) had ALC less 5 × 109/L. Patients 109/L lower rates cytogenetic abnormalities (P = .0002) higher CD38-positive resul...

参考文章(40)
Francesca R. Mauro, Robert Foa, Diana Giannarelli, Iole Cordone, Sabrina Crescenzi, Edoardo Pescarmona, Roberta Sala, Raffaella Cerretti, Franco Mandelli, Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood. ,vol. 94, pp. 448- 454 ,(1999) , 10.1182/BLOOD.V94.2.448
Alejandro H. Preti, Andreas H. Sarris, Odeal Pate, Anas Younes, Jorge E. Romaguera, Nam H. Dang, Peter Mclaughlin, Fernando Cabanillas, Maria A. Rodriguez, Nancy Mcada, Ming-Sheng Lee, Fredrick B. Hagemeister, Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Seminars in Oncology. ,vol. 27, pp. 37- 41 ,(2000)
Bertold Emmerich, Dagmar Adorf, Christoph Nerl, Michael Hallek, Raymonde Busch, Wolfgang Knauf, Eckhard Thiel, Ingrid Kuhn-Hallek, Marianne Ostwald, Irmgard Langenmayer, Hermann Dietzfelbinger, Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood. ,vol. 93, pp. 1732- 1737 ,(1999) , 10.1182/BLOOD.V93.5.1732
KR Rai, A Sawitsky, EP Cronkite, AD Chanana, RN Levy, BS Pasternack, Clinical staging of chronic lymphocytic leukemia. Blood. ,vol. 46, pp. 219- 234 ,(1975) , 10.1182/BLOOD.V46.2.219.219
C Rozman, E Montserrat, J C Reverter, N Viñolas, Natural history of chronic lymphocytic leukemia: on the progression and progression and prognosis of early clinical stages. Nouvelle revue française d'hématologie. ,vol. 30, pp. 359- 361 ,(1988)
S O'Brien, H Kantarjian, M Beran, T Smith, C Koller, E Estey, LE Robertson, S Lerner, M Keating, Results of Fludarabine and Prednisone Therapy in 264 Patients With Chronic Lymphocytic Leukemia With Multivariate Analysis-Derived Prognostic Model for Response to Treatment Blood. ,vol. 82, pp. 1695- 1700 ,(1993) , 10.1182/BLOOD.V82.6.1695.1695
E Montserrat, F Gomis, T Vallespi, A Rios, A Romero, J Soler, A Alcala, M Morey, C Ferran, J Diaz-Mediavilla, Presenting features and prognosis of chronic lymphocytic leukemia in younger adults [see comments] Blood. ,vol. 78, pp. 1545- 1551 ,(1991) , 10.1182/BLOOD.V78.6.1545.BLOODJOURNAL7861545
SM Hubbard, BA Chabner, VT Jr DeVita, R Simon, CW Berard, RB Jones, AJ Garvin, GP Canellos, CK Osborne, RC Young, Histologic progression in non-Hodgkin's lymphoma. Blood. ,vol. 59, pp. 258- 264 ,(1982) , 10.1182/BLOOD.V59.2.258.258
David G. Oscier, Anne C. Gardiner, Sarah J. Mould, Sharron Glide, Zadie A. Davis, Rachel E. Ibbotson, Martin M. Corcoran, Robert M. Chapman, Peter W. Thomas, J. Adrian Copplestone, Jenny A. Orchard, Terry J. Hamblin, Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. ,vol. 100, pp. 1177- 1184 ,(2002) , 10.1182/BLOOD.V100.4.1177.H81602001177_1177_1184